NEWS - Ovarian Cancer 101
NEWS 2017-09-21T19:47:34+00:00
  • Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer
    by Carolina Henriques on January 19, 2018 at 6:34 pm

    This post was originally published on this site A new Phase 1b clinical trial testing a combination treatment of Hu5F9-G4 with avelumab in patients with ovarian cancer is set to begin as part of an agreement between Forty Seven and Merck KGaA, Darmstadt, Germany. “Ovarian cancer patients have limited treatment options, especially as they are often diagnosed at a late […] The post Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer appeared first on BioNewsFeeds. […]

  • Phase 1 Trial for Prolanta in Advanced Ovarian Cancer Recruiting for Second Dose Group
    by Carolina Henriques on January 17, 2018 at 9:34 pm

    This post was originally published on this site Oncolix has started enrolling patients for the second dosing group in a Phase 1 trial of Prolanta for the treatment of advanced ovarian cancer. In the first dose group, Prolanta caused no serious adverse events or dose-limiting toxicity. Prolanta is a prolactin receptor antagonist (or blocker) that […] The post Phase 1 Trial for Prolanta in Advanced Ovarian Cancer Recruiting for Second Dose Group appeared first on BioNewsFeeds. […]

  • Celsion to Initiate Phase 1/2 Trial of GEN-1 in Newly-diagnosed Ovarian Cancer Patients
    by admin on January 15, 2018 at 9:02 pm

    This post was originally published on this site A Phase 1/2 trial to evaluate the DNA-based immunotherapy GEN-1 in patients with newly-diagnosed advanced ovarian cancer has been cleared by the U.S. Food and Drug Administration (FDA) without restrictions, Celsion announced. Recruitment for Phase 1 of the trial, called OVATION II (NCT03393884), is expected to begin by July this […] The post Celsion to Initiate Phase 1/2 Trial of GEN-1 in Newly-diagnosed Ovarian Cancer Patients appeared first on BioNewsFeeds. […]

  • Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors
    by admin on January 12, 2018 at 4:16 pm

    This post was originally published on this site A Phase 1/2a trial of Immix Biopharma’s IMX-110, a combination treatment targeting advanced solid tumors, including ovarian cancer, has received the necessary ethics board approval to begin. The trial (NCT03382340) will explore the safety, tolerability, and pharmacokinetics (how the body metabolizes, distributes, and excretes a medicine) of […] The post Immix to Initiate Phase 1/2a Trial of IMX-110 in Ovarian, Other Solid Tumors appeared first on BioNewsFeeds. […]

  • Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment
    by Carolina Henriques on January 10, 2018 at 2:31 pm

    This post was originally published on this site Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab). Myriad’s myChoice HRD Plus is a test for BRCA1 and BRCA2 tumor status, as well as […] The post Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment appeared first on BioNewsFeeds. […]

  • Fluorescent Nanoparticles May Help to Spot Cancer Cells Surgeons Could Easily Miss
    by admin on January 5, 2018 at 4:34 pm

    This post was originally published on this site A fluorescent nanomedicine tool for cancer may help to identify which tissues to remove, as well as to kill malignant cells that can’t be cut out with surgery, a new study from Oregon State University reports. The study, “A Tumor-Activatable Theranostic Nanomedicine Platform for NIR Fluorescence-Guided Surgery […] The post Fluorescent Nanoparticles May Help to Spot Cancer Cells Surgeons Could Easily Miss appeared first on BioNewsFeeds. […]

  • Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer
    by Magdalena Kegel on January 3, 2018 at 3:55 pm

    This post was originally published on this site Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, which are boosted to fight the tumor by exposure to tumor proteins. The trial is running at […] The post Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer appeared first on BioNewsFeeds. […]

  • Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers
    by admin on December 22, 2017 at 2:31 pm

    This post was originally published on this site Initial data from an early clinical trial in patients with advanced ovarian and other cancers found a potential oral therapy, COTI-2, to be safe at varying doses, supporting a more advanced Phase 2 trial in these people, Critical Outcome Technologies announced. “We are encouraged to see these PK [pharmacokinetic] data […] The post Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers appeared first on BioNewsFeeds. […]

  • Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany
    by admin on December 20, 2017 at 7:48 pm

    This post was originally published on this site Zejula (niraparib), an oral therapy for patients with recurrent ovarian cancer, is now available in Germany, according to Tesaro, the biopharma that developed the therapy. “The introductions of Zejula in Germany and the UK are significant milestones for TESARO as we bring transformative therapies to patients with cancer around […] The post Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany appeared first on BioNewsFeeds. […]

  • Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures
    by admin on December 18, 2017 at 9:02 pm

    This post was originally published on this site Researchers discovered how AB Science’s therapy masitinib — a veterinary medicine sold as Kinavet in the U.S. — acts to re-sensitize drug-resistant tumor cells to the anti-cancer treatment Gemzar (gemcitabine). The discovery could lead to better treatments for diseases where nucleoside analogues like Gemzar are used as […] The post Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures appeared first on BioNewsFeeds. […]